Keros Therapeutics Initiates DMD Trial and Plans ALS Phase II Discussions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 28 2026
0mins
Should l Buy KROS?
Source: Yahoo Finance
- DMD Trial Launch: Keros plans to initiate a clinical trial for Duchenne muscular dystrophy (DMD) with rinvatercept (KER-065) this quarter, while engaging regulators in the second half of the year to discuss a potential phase II program for ALS, indicating the company's proactive approach in neuromuscular disease development.
- Partnership Agreement: The collaboration with Takeda for elritercept includes a $200 million upfront payment and over $1.1 billion in potential milestone payments, with Takeda responsible for development in most territories, providing Keros with substantial funding support and market expansion opportunities.
- Clinical Trial Results: In phase I trials, KER-065 demonstrated good tolerability in healthy volunteers without dose-limiting toxicities or serious adverse events, suggesting potential benefits in muscle regeneration and bone health, which could lay the groundwork for future therapeutic options.
- Strong Financial Position: Keros reported $383 million in cash as of its third-quarter earnings, with an expected runway into the first half of 2028, ensuring sufficient financial backing for advancing DMD and ALS clinical trials along with other preclinical assets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KROS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KROS
Wall Street analysts forecast KROS stock price to rise
7 Analyst Rating
3 Buy
4 Hold
0 Sell
Moderate Buy
Current: 11.350
Low
16.00
Averages
21.20
High
27.00
Current: 11.350
Low
16.00
Averages
21.20
High
27.00
About KROS
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Keros Therapeutics Reports 2025 Financial Results and Pipeline Progress
- Improved Financial Performance: Keros Therapeutics reported a net loss of $23.5 million for Q4 2025, significantly down from $46 million in Q4 2024, indicating effective cost control and revenue growth strategies.
- Substantial Revenue Growth: Total revenue for 2025 reached $244.1 million, a dramatic increase from $3.6 million in 2024, primarily driven by licensing revenue from Takeda, showcasing the company's success in commercialization efforts.
- Clinical Development Progress: The pipeline includes Rinvatercept and Elritercept, with a Phase 2 trial for Rinvatercept targeting Duchenne muscular dystrophy set to begin in Q2 2026, reflecting the company's strategic focus on innovative therapies.
- Executive Changes and Financial Position: Keros ended 2025 with cash and cash equivalents of $287.4 million, expected to fund operations into the first half of 2028, while the appointment of new board members and a Chief Legal Officer will strengthen corporate governance.
See More
Keros Therapeutics Reports 2025 Financial Results and Strategic Updates
- Improved Financial Performance: Keros reported a net income of $87 million for the fiscal year 2025, a significant turnaround from a net loss of $187.4 million in 2024, indicating strong revenue growth and cost management that boosts investor confidence.
- Reduced R&D Expenses: Research and development expenses for Q4 2025 were $17.9 million, down from $45.6 million in Q4 2024, primarily due to the transition of certain R&D costs to Takeda, optimizing resource allocation and enhancing operational efficiency.
- Clinical Trial Advancements: Keros plans to initiate a Phase 2 clinical trial of rinvatercept for Duchenne muscular dystrophy in Q2 2026 and engage regulators on ALS trial design in the second half of 2026, demonstrating a proactive approach to product development and regulatory engagement.
- Leadership Changes: In February 2026, Charles Newton was appointed to the board, and Esther Cho was promoted to Chief Legal Officer, reflecting ongoing improvements in strategic execution and governance structure aimed at enhancing the company's long-term growth potential.
See More
Keros Therapeutics Initiates DMD Trial and Plans ALS Phase II Discussions
- DMD Trial Launch: Keros plans to initiate a clinical trial for Duchenne muscular dystrophy (DMD) with rinvatercept (KER-065) this quarter, while engaging regulators in the second half of the year to discuss a potential phase II program for ALS, indicating the company's proactive approach in neuromuscular disease development.
- Partnership Agreement: The collaboration with Takeda for elritercept includes a $200 million upfront payment and over $1.1 billion in potential milestone payments, with Takeda responsible for development in most territories, providing Keros with substantial funding support and market expansion opportunities.
- Clinical Trial Results: In phase I trials, KER-065 demonstrated good tolerability in healthy volunteers without dose-limiting toxicities or serious adverse events, suggesting potential benefits in muscle regeneration and bone health, which could lay the groundwork for future therapeutic options.
- Strong Financial Position: Keros reported $383 million in cash as of its third-quarter earnings, with an expected runway into the first half of 2028, ensuring sufficient financial backing for advancing DMD and ALS clinical trials along with other preclinical assets.
See More
Keros Therapeutics Appoints Charles Newton to Board of Directors
- New Board Appointment: Keros Therapeutics announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026, bringing extensive healthcare finance expertise that will support the company during critical value inflection points in its clinical programs, thereby enhancing its competitive position in the biopharmaceutical industry.
- Strategic Development Support: Newton expressed his intention to leverage his experience in guiding biotechnology companies through growth phases to advance the clinical development of rinvatercept (KER-065), which is expected to provide potential disease-modifying benefits to patients, further driving the company's long-term growth and value creation.
- Executive Transition: Concurrent with Newton's appointment, Carl Gordon, Ph.D., will step down from the Board on March 9, 2026, with Keros CEO Jasbir Seehra thanking Gordon for his contributions, emphasizing the stability and continuity in the company's board member transitions.
- Product Development Outlook: Keros focuses on developing innovative therapeutics targeting the TGF-β protein family, with its lead candidates rinvatercept and elritercept aimed at treating Duchenne muscular dystrophy and myelodysplastic syndromes, showcasing the company's potential and market opportunities in the biopharmaceutical sector.
See More
Five Low Price-to-Book Stocks to Buy: AES, BorgWarner, Enersys, PG&E, Keros
- Low P/B Stocks: The AES Corporation, BorgWarner, Enersys, PG&E, and Keros Therapeutics are highlighted as low price-to-book stocks to buy as 2025 approaches, indicating strong value recognition among investors.
- Growth Potential: AES has a projected 3-5 year EPS growth rate of 11.2%, while Keros Therapeutics boasts an impressive 36.5%, showcasing robust growth prospects in their respective sectors.
- Industry Rankings: Both AES and PG&E hold a Zacks Rank of #2, reflecting their strong market positions and attracting interest from value investors.
- Investment Strategy: By focusing on stocks with a P/B ratio below 1, investors can identify undervalued companies, thereby uncovering potential investment opportunities amidst market fluctuations.
See More
Zacks.com Spotlights StoneCo, General Motors, Enersys, Deutsche, and Keros
Value Stocks Overview: The article discusses various stocks including StoneCo, General Motors, Enersys, Deutsche Bank, and Keros Therapeutics, highlighting the importance of the price-to-book (P/B) ratio as a valuation tool for identifying undervalued stocks with growth potential.
Understanding Book Value: Book value is defined as the total value remaining for shareholders if a company were to liquidate, calculated by subtracting total liabilities from total assets, and is crucial for assessing whether a stock is under- or overpriced.
P/B Ratio Insights: A P/B ratio of less than one indicates a potentially undervalued stock, while a ratio above one suggests overvaluation; however, investors should be cautious as a low P/B can also signal poor asset returns or overstated assets.
Investment Recommendations: The article provides insights into the projected earnings growth rates for the mentioned companies, encouraging readers to consider these stocks for investment while also recommending the use of additional financial ratios for informed decision-making.
See More
Keros Therapeutics Reports 2025 Financial Results and Pipeline Progress
- Improved Financial Performance: Keros Therapeutics reported a net loss of $23.5 million for Q4 2025, significantly down from $46 million in Q4 2024, indicating effective cost control and revenue growth strategies.
- Substantial Revenue Growth: Total revenue for 2025 reached $244.1 million, a dramatic increase from $3.6 million in 2024, primarily driven by licensing revenue from Takeda, showcasing the company's success in commercialization efforts.
- Clinical Development Progress: The pipeline includes Rinvatercept and Elritercept, with a Phase 2 trial for Rinvatercept targeting Duchenne muscular dystrophy set to begin in Q2 2026, reflecting the company's strategic focus on innovative therapies.
- Executive Changes and Financial Position: Keros ended 2025 with cash and cash equivalents of $287.4 million, expected to fund operations into the first half of 2028, while the appointment of new board members and a Chief Legal Officer will strengthen corporate governance.
See More
Keros Therapeutics Reports 2025 Financial Results and Strategic Updates
- Improved Financial Performance: Keros reported a net income of $87 million for the fiscal year 2025, a significant turnaround from a net loss of $187.4 million in 2024, indicating strong revenue growth and cost management that boosts investor confidence.
- Reduced R&D Expenses: Research and development expenses for Q4 2025 were $17.9 million, down from $45.6 million in Q4 2024, primarily due to the transition of certain R&D costs to Takeda, optimizing resource allocation and enhancing operational efficiency.
- Clinical Trial Advancements: Keros plans to initiate a Phase 2 clinical trial of rinvatercept for Duchenne muscular dystrophy in Q2 2026 and engage regulators on ALS trial design in the second half of 2026, demonstrating a proactive approach to product development and regulatory engagement.
- Leadership Changes: In February 2026, Charles Newton was appointed to the board, and Esther Cho was promoted to Chief Legal Officer, reflecting ongoing improvements in strategic execution and governance structure aimed at enhancing the company's long-term growth potential.
See More
Keros Therapeutics Initiates DMD Trial and Plans ALS Phase II Discussions
- DMD Trial Launch: Keros plans to initiate a clinical trial for Duchenne muscular dystrophy (DMD) with rinvatercept (KER-065) this quarter, while engaging regulators in the second half of the year to discuss a potential phase II program for ALS, indicating the company's proactive approach in neuromuscular disease development.
- Partnership Agreement: The collaboration with Takeda for elritercept includes a $200 million upfront payment and over $1.1 billion in potential milestone payments, with Takeda responsible for development in most territories, providing Keros with substantial funding support and market expansion opportunities.
- Clinical Trial Results: In phase I trials, KER-065 demonstrated good tolerability in healthy volunteers without dose-limiting toxicities or serious adverse events, suggesting potential benefits in muscle regeneration and bone health, which could lay the groundwork for future therapeutic options.
- Strong Financial Position: Keros reported $383 million in cash as of its third-quarter earnings, with an expected runway into the first half of 2028, ensuring sufficient financial backing for advancing DMD and ALS clinical trials along with other preclinical assets.
See More
Keros Therapeutics Appoints Charles Newton to Board of Directors
- New Board Appointment: Keros Therapeutics announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026, bringing extensive healthcare finance expertise that will support the company during critical value inflection points in its clinical programs, thereby enhancing its competitive position in the biopharmaceutical industry.
- Strategic Development Support: Newton expressed his intention to leverage his experience in guiding biotechnology companies through growth phases to advance the clinical development of rinvatercept (KER-065), which is expected to provide potential disease-modifying benefits to patients, further driving the company's long-term growth and value creation.
- Executive Transition: Concurrent with Newton's appointment, Carl Gordon, Ph.D., will step down from the Board on March 9, 2026, with Keros CEO Jasbir Seehra thanking Gordon for his contributions, emphasizing the stability and continuity in the company's board member transitions.
- Product Development Outlook: Keros focuses on developing innovative therapeutics targeting the TGF-β protein family, with its lead candidates rinvatercept and elritercept aimed at treating Duchenne muscular dystrophy and myelodysplastic syndromes, showcasing the company's potential and market opportunities in the biopharmaceutical sector.
See More
Five Low Price-to-Book Stocks to Buy: AES, BorgWarner, Enersys, PG&E, Keros
- Low P/B Stocks: The AES Corporation, BorgWarner, Enersys, PG&E, and Keros Therapeutics are highlighted as low price-to-book stocks to buy as 2025 approaches, indicating strong value recognition among investors.
- Growth Potential: AES has a projected 3-5 year EPS growth rate of 11.2%, while Keros Therapeutics boasts an impressive 36.5%, showcasing robust growth prospects in their respective sectors.
- Industry Rankings: Both AES and PG&E hold a Zacks Rank of #2, reflecting their strong market positions and attracting interest from value investors.
- Investment Strategy: By focusing on stocks with a P/B ratio below 1, investors can identify undervalued companies, thereby uncovering potential investment opportunities amidst market fluctuations.
See More
Zacks.com Spotlights StoneCo, General Motors, Enersys, Deutsche, and Keros
Value Stocks Overview: The article discusses various stocks including StoneCo, General Motors, Enersys, Deutsche Bank, and Keros Therapeutics, highlighting the importance of the price-to-book (P/B) ratio as a valuation tool for identifying undervalued stocks with growth potential.
Understanding Book Value: Book value is defined as the total value remaining for shareholders if a company were to liquidate, calculated by subtracting total liabilities from total assets, and is crucial for assessing whether a stock is under- or overpriced.
P/B Ratio Insights: A P/B ratio of less than one indicates a potentially undervalued stock, while a ratio above one suggests overvaluation; however, investors should be cautious as a low P/B can also signal poor asset returns or overstated assets.
Investment Recommendations: The article provides insights into the projected earnings growth rates for the mentioned companies, encouraging readers to consider these stocks for investment while also recommending the use of additional financial ratios for informed decision-making.
See More
